You are viewing: Europe Cell Therapy Technologies Market analysis

The Europe Cell Therapy Technologies Market was valued at $580 Million in 2025 and projected to reach to $1057.2 Million by 2030, representing a compound annual growth rate of 12.8%. Europe's cell therapy technologies market is poised for accelerated growth driven by increasing regulatory approvals, expanding clinical applications, and substantial public-private partnerships in regenerative medicine.

Europe Cell Therapy Technologies Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Europe Cell Therapy Technologies Market Trends and Insights

  • This 12.8% compound annual growth rate reflects Europe's strong regulatory framework, advanced healthcare infrastructure, and significant investment in regenerative medicine research.
  • Europe is positioning itself as a global leader in cell therapy innovation, with established manufacturing capabilities and a growing pipeline of approved therapies. The European market benefits from supportive regulatory pathways, including the Advanced Therapy Medicinal Products (ATMP) framework, which streamlines approval for cell-based treatments.
  • Europe's commitment to precision medicine and personalized healthcare is driving adoption across oncology, immunology, and degenerative disease applications.
  • Between 2025 and 2030, Europe is expected to see accelerated commercialization of CAR-T therapies, stem cell treatments, and engineered cell products, supported by increasing healthcare expenditure and public-private partnerships. Europe's competitive advantage lies in its scientific expertise, collaborative research networks, and patient-centric regulatory environment.
  • The region's market growth is underpinned by rising prevalence of chronic diseases, aging populations, and growing clinical evidence supporting cell therapy efficacy.
  • Europe is anticipated to maintain its position as a key innovation hub, attracting investment and talent in cell therapy development through 2030..

Key Market Statistics

  • CAGR (2025-2030) 12.8% CAGR
  • Market Size, 2025 ~USD 580 Million
  • Forecast, 2030 ~USD 1057.2 Million
  • Geography Europe

Europe Cell Therapy Technologies Market Overview

Market Valuation & Growth :

Europe's cell therapy technologies market is valued at $580.0 million in 2025, with a robust 12.8% CAGR projected through 2030, reaching $1,057.2 million. This growth rate exceeds the global average of 12.4%, positioning Europe as a high-growth region.

Regulatory Leadership :

Europe's advanced regulatory framework, including EMA approval pathways and ATMP guidelines, provides a competitive advantage for cell therapy development and commercialization, attracting significant R&D investment from global biotech companies.

Healthcare Infrastructure :

Europe's sophisticated healthcare systems, coupled with strong government funding for regenerative medicine research, create an ideal ecosystem for cell therapy innovation and clinical adoption across multiple therapeutic areas.

Regional Market Concentration :

Germany leads European adoption with $344.9 million in market size, followed by the UK ($238.3M) and France ($212.7M), collectively representing over 80% of the European cell therapy market opportunity.

Europe Cell Therapy Technologies Market Dynamics

  • The region's commitment to advanced manufacturing capabilities and personalized medicine approaches strengthens its competitive position globally.
  • Investment in CAR-T cell therapies, stem cell treatments, and tissue engineering continues to surge across major European markets. The forecast period through 2030 will witness consolidation among European biotech firms, increased adoption in oncology and immunology, and growing patient access to cell-based therapies.
  • Collaboration between academic institutions and industry, combined with favorable reimbursement policies in key markets, will drive market expansion.
  • Europe's focus on quality standards and ethical frameworks positions it as a trusted hub for cell therapy innovation and manufacturing..

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Key Takeaways

    • Europe's cell therapy market is valued at $580.0M in 2025 and projected to grow to $1,057.2M by 2030, representing a 12.8% CAGR.
    • Europe's ATMP regulatory framework provides a competitive advantage, enabling faster approval and commercialization of cell-based therapies compared to other regions.
    • CAR-T therapies, stem cell treatments, and engineered cell products are driving market expansion across Europe's oncology and immunology segments.
    • Europe's aging population and rising chronic disease prevalence are key growth catalysts, supported by strong healthcare infrastructure and R&D investment.

    Cell Therapy Technologies Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment MEDIA, SERA, AND REAGENTS (Product)
    Forecast Period 2025–2030
    Growth Rate CAGR of 12.4% from 2025 to 2030
    Largest Segment T-CELLS (Cell Type)
    Market Size Base Year (Billions) ~USD 4.41 (2025)
    Revenue Forecast (Billions) ~USD 7.91 (2030)
    Segments Covered Product, Type, Process, Cell Type

    Europe Cell Therapy Technologies Market Report Segmentation

    4 segment dimensions are covered across the global market.

    By Product

    • Cell Culture Vessels
    • Cell Engineering Products
    • Cell Therapy Equipment
    • Media, Sera, And Reagents
    • Other Products
    • Systems & Software

    By Type

    • Cell Characterization
    • Cell Collection
    • Cell Expansion
    • Cell Isolation
    • Cell Processing Equipment
    • Other Cell Therapy Equipment
    • Single-Use Equipment

    By Process

    • Cell Distribution
    • Cell Handling
    • Cell Preservation
    • Cell Processing
    • Process Monitoring And Quality Control

    By Cell Type

    • Other Cells
    • Stem Cells
    • T-Cells

    EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES488.7505.8552.7609.4679765.4874.5101612.9
    CELL BANKS82.785.690.696.7104.2113.6125.5140.89.2
    CROS & CMOS397412.1445485534.1595.1672.2772.111.6
    RESEARCH INSTITUTES137.2140.9151163.3178.4197.1220.8251.510.7
    TOTAL1105.61144.41239.31354.41495.71671.31892.92180.412

    REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES37.643.546.149.253.157.963.871.59.2
    CELL BANKS6.47.47.67.98.28.79.2105.6
    CROS & CMOS30.635.437.139.241.84549.154.47.9
    RESEARCH INSTITUTES10.512.112.513.113.914.816.117.67
    TOTAL85.198.4103.4109.4117126.3138.2153.58.2

    Target Audience

    • Pharmaceutical & Biotech Companies : Develop market entry strategies, assess competitive positioning, and identify acquisition targets in Europe's high-growth cell therapy sector with detailed country-level market data.
    • Healthcare Investors & PE Firms : Evaluate investment opportunities in European cell therapy companies and technologies with comprehensive market sizing, growth projections, and regional opportunity assessments.
    • Medical Device & Diagnostics Manufacturers : Understand European cell therapy market dynamics to identify partnership opportunities, complementary product development, and distribution channel expansion strategies.
    • Healthcare Policy & Regulatory Bodies : Access market intelligence on cell therapy adoption, reimbursement trends, and clinical outcomes across European countries to inform policy development and healthcare planning.
    • Academic & Research Institutions : Benchmark European cell therapy research commercialization potential, identify funding opportunities, and understand market demand for emerging therapeutic innovations.

    Key Companies in the Europe Cell Therapy Technologies Market

    CompanyHQOwnershipStrongest segments
    GENERAL ELECTRICUnited StatesPublic CompanyCommercial Engines & Services,Defense & Propulsion Technologies,Additive, Components, and Other Systems,
    MERCK KGAAGermanyPublic CompanyLife Science (reagents, consumables, instruments, bioprocessing, CDMO/testing services),Healthcare (prescription drugs and biopharmaceuticals),Electronics (semiconductor materials, specialty gases, display and OLED materials, delivery equipment),
    SARTORIUS AGGermanyPublic CompanyBioprocess solutions (bioreactors, filtration, fluid management, process chromatography),Lab products and services (weighing, pipettes, lab filtration, water systems, microbiological testing),Advanced analytics and PAT (BLI, cytometry screening, SPR, live-cell imaging, data analytics),
    FRESENIUS SE & CO. KGAAGermanyPublic CompanyFresenius Helios (hospitals and care centers),IV generics and IV fluids,Clinical nutrition (enteral and parenteral),
    CORNING INCORPORATEDUnited StatesPublic CompanyOptical communications (fiber, cable, hardware, connectivity),Display glass substrates (LCD and OLED),Specialty materials (mobile, semiconductor optics, aerospace, defense, sunglasses, shielding),
    TERUMO CORPORATIONJapanPublic CompanyCardiac and Vascular Company,Medical Care Solutions Company,Blood and Cell Technologies Company,
    BIO-TECHNEUnited StatesPublic CompanyProtein Sciences reagents and proteomic tools,Diagnostics controls, calibrators, and assays,Spatial biology and advanced genomic assays,
    GENSCRIPTHong KongPublic CompanyLife Science Services and Products,Biologics Development Services,Industrial Synthetic Biology Products,
    MAXCYTEUnited StatesPublic CompanyExPERT GTx and VLx (large and very large scale therapeutic applications),ExPERT STx (flow electroporation for protein production and drug development),ExPERT ATx (static electroporation for small to medium scale),

    GENERAL ELECTRIC

    General Electric is a diversified American industrial conglomerate founded in 1892 that operates across multiple sectors including power, renewable energy, aviation, and healthcare. As a public company, GE employs approximately 57,000 people globally and maintains a significant presence in industrial manufacturing and technology.

    MERCK KGAA

    Merck KGaA is a German pharmaceutical, chemical, and life sciences company founded in 1668 with approximately 59,077 employees worldwide. Operating as a public company, Merck KGaA serves customers across the healthcare, life science, and performance materials sectors.

    SARTORIUS AG

    Sartorius AG is a German life sciences and laboratory equipment company founded in 1870 with 14,242 employees. As a public company, Sartorius specializes in bioprocess solutions, laboratory instruments, and weighing technology for pharmaceutical and biotechnology industries.

    FRESENIUS SE & CO. KGAA

    Fresenius SE & Co. KGaA is a German healthcare company founded in 1912 with 177,783 employees, making it one of the largest healthcare service providers globally. Operating as a public company, Fresenius provides dialysis products and services, hospital care, and pharmaceutical products.

    CORNING INCORPORATED

    Corning Incorporated is an American materials science company founded in 1851 with 67,200 employees that specializes in glass, ceramics, and optical physics. As a public company, Corning serves industries including telecommunications, display technology, environmental solutions, and life sciences.

    TERUMO CORPORATION

    Terumo Corporation is a Japanese medical device and pharmaceutical company founded in 1921 with 30,591 employees. As a public company, Terumo develops and manufactures products for cardiovascular systems, general hospital care, transfusion and cell therapy, and vascular intervention.

    BIO-TECHNE

    Bio-Techne is an American life sciences company founded in 1976 with 3,100 employees that provides tools and reagents for research and diagnostics. Operating as a public company, Bio-Techne serves the biotechnology, pharmaceutical, and academic research sectors.

    GENSCRIPT

    GenScript is a Hong Kong-based biotechnology company founded in 2002 with 6,165 employees specializing in synthetic biology and life science research services. As a public company, GenScript provides gene synthesis, protein production, and drug discovery solutions to pharmaceutical and research organizations.

    MAXCYTE

    MaxCyte is a small American biotechnology company founded in 1998 with 91 employees focused on cell engineering and manufacturing technologies. Operating as a public company, MaxCyte develops platforms for ex vivo cell therapy production.

    Europe vs. other regions

    HowEurope compares to the other 3 regional blocs covered in this market.

    North America
    ~USD 1516.6 Million · 13.5% wtd CAGR ·
    Asia Pacific
    ~USD 989.9 Million · 14.7% wtd CAGR ·
    Latin America
    ~USD 184 Million · 9.4% wtd CAGR ·

    Countries within Europe - compare and drill down

    Country2025 size (native)
    GermanyUSD 344.9 Million
    UKUSD 238.3 Million
    FranceUSD 212.7 Million
    ItalyUSD 101.9 Million
    SpainUSD 85.5 Million
    Rest Of EuropeUSD 74 Million

    Country market size visualization

    Germany
    USD 344.9 Million
    UK
    USD 238.3 Million
    France
    USD 212.7 Million
    Italy
    USD 101.9 Million
    Spain
    USD 85.5 Million
    Rest Of Europe
    USD 74 Million

    Reasons to Buy this Report

    • Market Size & Growth Data : Access comprehensive market valuation for Europe at $580.0M (2025) with detailed 12.8% CAGR projections through 2030, enabling accurate financial forecasting and investment planning.
    • Country-Level Insights : Granular market data for Germany ($344.9M), UK ($238.3M), France ($212.7M), Italy, Spain, and Rest of Europe breakdown, identifying high-opportunity markets for expansion and partnership.
    • Competitive Landscape Analysis : Understand Europe's regulatory advantages, manufacturing capabilities, and key players driving innovation in cell therapy, essential for market entry and competitive positioning strategies.
    • Strategic Investment Guidance : Identify emerging opportunities in European cell therapy segments, reimbursement trends, and clinical adoption patterns to optimize R&D investment and commercialization timelines.
    • Regulatory & Market Intelligence : Leverage insights on EMA approval pathways, ATMP guidelines, and European healthcare policies to navigate regulatory requirements and accelerate product launches across the region.

    Frequently asked questions

    What is the current size of Europe's cell therapy technologies market?

    Europe's cell therapy technologies market is valued at $580.0 million in 2025 and is projected to reach $1,057.2 million by 2030, growing at a 12.8% CAGR.

    What regulatory framework supports cell therapy development in Europe?

    Europe's Advanced Therapy Medicinal Products (ATMP) framework provides a streamlined regulatory pathway for cell-based therapies, enabling faster approval and market entry compared to traditional drug approval processes.

    Which cell therapy types are driving growth in Europe?

    CAR-T cell therapies, stem cell treatments, and engineered cell products are the primary drivers of market growth in Europe, particularly in oncology and immunology applications.

    What factors are accelerating Europe's cell therapy market expansion?

    Europe's market growth is driven by an aging population, rising prevalence of chronic diseases, strong healthcare infrastructure, significant R&D investment, and supportive regulatory policies that encourage innovation.

    How does Europe's cell therapy market compare to global trends?

    Europe's 12.8% CAGR slightly exceeds the global average of 12.4%, reflecting the region's advanced regulatory environment, scientific expertise, and strong commitment to regenerative medicine innovation.

    RESEARCH METHODOLOGY

    This research study utilized extensive secondary sources, directories, and databases to identify and collect valuable information for analyzing the global cell therapy technologies market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to gather and verify critical qualitative and quantitative information and assess the market's growth prospects. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

    Secondary Research

    Secondary research was primarily used to identify and collect information for the comprehensive, technical, market-oriented, and commercial study of the cell therapy technologies market. The secondary sources used for this study include FDA (US Food and Drug Administration), EMA (European Medicines Agency), NIH (National Institutes of Health), ClinicalTrials.gov, PMDA (Pharmaceuticals and Medical Devices Agency, Japan), MHRA (Medicines and Healthcare products Regulatory Agency, UK), European Society of Gene and Cell Therapy (ESGCT), California Institute for Regenerative Medicine (CIRM), World Health Organization (WHO), International Society for Cell & Gene Therapy (ISCT), CBER (Center for Biologics Evaluation and Research), NIH Regenerative Medicine Program, National Medical Products Administration (NMPA), China, Health Canada – Biologics and Genetic Therapies Directorate (BGTD), Eurostat, Factiva, and GLOBOCAN, ScienceDirect; research journals; corporate filings, such as annual reports, SEC filings, investor presentations, and financial statements; press releases; and trade, business, and professional associations, among others. These sources were also utilized to gather key information about major players, market classification, and segmentation, as well as industry trends, regional/country-level markets, market developments, and technological perspectives.

    Primary Research

    After acquiring foundational knowledge about the global cell therapy technologies market through secondary research, extensive primary research was conducted. Multiple interviews were held with market experts from the demand side, including representatives from biopharmaceutical & biotechnology companies, CROs and CMOs, research institutes, and cell banks. Additionally, experts from the supply side were interviewed, including C-level and D-level executives, product managers, and marketing and sales managers from key manufacturers, distributors, and channel partners.

    These interviews spanned six major regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Approximately 70% of the primary interviews were conducted with supply-side participants, while the remaining 30% were with demand-side participants. The primary data was collected through various methods, including questionnaires, emails, online surveys, personal interviews, and telephone interviews.

    The following is a breakdown of the primary respondents:

    Cell Therapy Technologies Market

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    Both top-down and bottom-up approaches were used to estimate and validate the total size of the cell therapy technologies market. These methods were also used extensively to estimate the size of various market segments. The research methodology used to estimate the market size includes the following:

    After determining the overall market size through the estimation process, the total market was divided into several segments and subsegments.

    Cell Therapy Technologies Market

    Data Triangulation

    After determining the market size through the estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and obtain precise statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, as applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

    Market Definition

    Cell therapy is a transformative area that represents a groundbreaking advancement in modern medicine, leveraging living cells to repair, replace, or regenerate damaged tissues and treat a wide range of diseases. This innovative approach involves introducing functional cells into a patient’s body to restore health, offering solutions for conditions that were once considered untreatable. With applications spanning autologous therapies, which utilize a patient’s cells, and allogeneic therapies, offering scalable off-the-shelf solutions, cell therapy is transforming healthcare delivery. The report encompasses a range of media, sera, reagents, cell engineering products, cell therapy equipment, software, and other products utilized at various stages of cell therapy, including cell collection, manufacturing, expansion, and storage.

    Stakeholders

    • Cell therapy product manufacturers, suppliers, and processors
    • Distributors and suppliers of cell therapy products
    • Biotechnology and biopharmaceutical companies
    • Contract manufacturing organizations (CMOs)
    • Suppliers and distributors of pharmaceutical products
    • Research and development (R&D) companies
    • Pharmaceutical/medical associations
    • Trade associations and industry bodies
    • Regulatory bodies and government agencies
    • Research institutes and government organizations
    • Venture capitalists and investors
    • Business research and consulting service providers
    • Market research and consulting firms

    Report Objectives

    • To define, describe, and forecast the cell therapy technologies market based on product, process, cell type, application, end user, and region
    • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
    • To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall cell therapy technologies market
    • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to six main regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
    • To profile the key players in the global cell therapy technologies market and comprehensively analyze their product portfolios, market positions, and core competencies2
    • To track and analyze competitive developments such as product launches, acquisitions, partnerships, expansions, agreements, and collaborations in the cell therapy technologies market
    • To benchmark players within the cell therapy technologies market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and business strategy

     

    Get the Full Cell Therapy Technologies Market Report

    Full forecast, segment splits, and company analysis for all Cell Therapy Technologies Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status